Table 5. Factors affected treatment outcomes: univariate and multivariate analysis.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Pathological result (SCC vs. ADC) | 1.19 | 0.70–2.00 | 0.528 | 1.15 | 0.67–1.98 | 0.620 |
| Histologic grade (I–II vs. III) | 1.79 | 1.43–2.24 | <0.001 | 1.51 | 1.19–1.91 | <0.001 |
| Preteatment Hb level (<10 vs. ≥10) | 0.66 | 0.39–1.11 | 0.115 | 0.84 | 0.50–1.44 | 0.531 |
| Stage (I–II vs. III) | 1.82 | 1.46–2.27 | <0.001 | 1.72 | 1.35–2.18 | <0.001 |
| Treatment modality (RT vs. CCRT) | 0.85 | 0.47–1.53 | 0.582 | 0.91 | 0.50–1.65 | 0.746 |
| TTT (≤56 days vs. >56 days) | 1.33 | 0.87–2.05 | 0.194 | 1.22 | 0.78–1.90 | 0.380 |
| HDR brachytherapy source (Ir-192 vs. Co-60) | 0.78 | 0.49–1.23 | 0.286 | 0.94 | 0.58–1.51 | 0.798 |
ADC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; CI, confidence interval; Co-60, cobalt-60; Hb, hemoglobin; HR, hazard ratio; Ir-192, iridium-192; RT, radiotherapy; SCC, squamous cell carcinoma; TTT, total treatment time.